We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tiziana Life Sciences Plc | LSE:TILS | London | Ordinary Share | GB00BKWNZY55 | ORD 3P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 58.50 | 45.00 | 60.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
14/1/2021 13:05 | Amazed that the nasal dosage is 100ug that’s 1 10thousandth of a gram. And easy to use ,so will be a lot lot cheaper to buy and administer. | impala391 | |
14/1/2021 12:59 | Good afternoon my little munchkin | markstevenkirby80 | |
14/1/2021 12:42 | LastOne aintEven generatingMillions InUk so.... millionPump CummingsTo ends ere | andymunchkin | |
14/1/2021 12:22 | Nice one Mark. Thanks for sharing. Gw | ih_451482 | |
14/1/2021 12:17 | 'I just read this article in arm chair trader, from an interview with GC on 7th Jan, note the dates in the last paragraph, excellent news for next week. here is the part that matters.Monoclonal antibody market is worth billions of dollarsForalumab, the drug that has just completed clinical trials in Brazil, is a human monoclonal antibody. Human monoclonal antibody, the world's first, is an antibody cloned from a single cell and has proven more successful than a monoclonal antibody developed from mice, which the human body rejects more frequently. The monoclonal antibody market is worth multiple billions of dollars as it can be used to treat not only COVID and Chron's disease but also diabetes, multiple sclerosis and other major illnesses. A successful drug in this space, particularly one that can be used fairly easily in form of a nasal spray, would have massive first mover advantage.Further information about the state of its pipeline could be provided on 18 January when the company will publish its prospectus ahead of its first trading day on the London Stock Exchange on 21 January.' | mark0419 | |
14/1/2021 10:44 | Will be good start | ivan danko | |
14/1/2021 10:31 | Zak Mir reiterating his 230-250p call for these again last night. | jpuff | |
14/1/2021 09:59 | You mean university payments. They close no or people still studying for degree. Why they not come.into tils make money i not understand | ivan danko | |
14/1/2021 09:26 | Cup & handle, the latter now being created | yidarmytom | |
14/1/2021 09:25 | Universal credit payments have been slightly reduced, that will account for some people ;o-/ | yidarmytom | |
14/1/2021 09:13 | Folk taking profit, January is hard month I suppose. A tad risky profit taking when a silver bullet RNS due.... | fandagle | |
14/1/2021 08:11 | Not showing large buys umm | ic0gcds00 | |
14/1/2021 07:09 | God Wlling | yidarmytom | |
13/1/2021 20:33 | This month i very sure. May we get good price waiting long time now..need new clothes | ivan danko | |
13/1/2021 20:33 | Ok my friend ....you let me know when you ready i help you.. | ivan danko | |
13/1/2021 20:12 | Any ideas when accuwtem might appear? No updates I've heard of yet | dmdmdmdm1 | |
13/1/2021 19:59 | Sounds good | ic0gcds00 | |
13/1/2021 18:49 | Almost forgot about my Accustem stash for a minute, share price going great guns, every day is a (5) and the bonus ball lottery win, happy trading.... | fandagle | |
13/1/2021 18:45 | We have to be strong in UK...i dont want east meet west again...like apollo lose to me..i beat old man... | ivan danko | |
13/1/2021 18:44 | Of course you very welcome but you must train hard in boxing gym...and you drink vodka not water when training ok?!! | ivan danko | |
13/1/2021 18:11 | US listing is being played as we are, 100%! | rebelwithacause1 | |
13/1/2021 17:41 | Imp your so hilarious! | rebelwithacause1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions